Zometa (zoledronic acid) has been touted as a life-saving drug, based on research in the February New England Journal of Medicine. And it looks like the drug has serious potential—for women with hormone-positive disease. Some things for women with hormone-negative breast cancer, including triple negative, to consider:
• The women studied were all premenopausal who were hormone-positive and were given hormonal therapy—either tamoxifen or Arimidex—plus goserelin (Zoladex) to suppress ovarian function.
• None received adjuvant (after surgery) chemotherapy;
• The study found a 98 percent chance of survival in young women who were given ovarian suppression and hormone therapy drugs but did receive any chemotherapy.
So this could be great news for a narrow group of women. Unfortunately, this does not include those of us with hormone-negative disease.
The Dr. Susan Love Research Foundation has a great analysis of this.
Back to the drawing board, docs. Find us a cure.
(My thanks to the talented Deb Lattimore for sending me Dr. Love’s link. You can read about Deb’s fight against triple negative, and enjoy her excellent photography, here. )